Table 1.
Patient demographics and baseline characteristics.
| Patient Characteristics | 62 Eyes (46 Patients) |
|---|---|
| Mean age, years (SD) | 71.6 (8.9) |
| Sex Female, n (%) | 25 (54.3) |
| Mean DM duration, years (SD) | 25.0 (12.1) |
| DM type, n (%) Type 1 Type 2 |
7 (15.2) 39 (84.8) |
| Mean DME duration, months (SD) | 60.3 (30.6) |
| Mean follow-up duration, months (SD) Eyes followed, n (%) >6 months >12 months >18 months >24 months |
13.9 (7.5) 50 (80.6) 38 (61.3) 24 (38.7) 4 (0.6) |
| Mean baseline IOP, mmHg (SD) | 13.4 (2.7) |
| Mean HbA1c, % (SD) | 7.9 (1.3) |
| Pseudophakic eyes, n (%) | 60 (96.8) |
| History of vitrectomy, n (%) | 18 (29.0) |
| Bilateral Fac injections, n (%) | 16 (34.8) |
| Mean baseline BCVA, ETDRS letters (SD) | 64.0 (17.2) |
| Mean baseline CMT, µm (SD) | 333.3 (112.5) |
| Mean number of previous intravitreal injections, n (SD) | 16.0 (9.1) |
| Anti-VEGF Ranibizumab Aflibercept Bevacizumab |
9.2 (6.0) in 52 eyes (83.9%) 6.4 (4.8) in 32 eyes (51.6%) 6.4 (3.7) in 42 eyes (67.7%) 2.0 (0.0) in 3 eyes (5%) |
| Corticosteroids Dexamethasone Triamcinolone |
8.2 (4.4) in 62 eyes (100%) 8.2 (4.2) in 62 eyes (100%) 2.25 (1.0) in 4 eyes (6.5%) |
| Laser, n (%): All Focal PRP Focal and PRP |
47 (75.8) 18 (29.0) 45 (72.6) 16 (25.8) |
| Baseline IOP-lowering therapy, n (%) None Monotherapy Dual therapy >Dual therapy History of IOP-lowering surgery Previous SLT |
41 (66.1) 11 (17.7) 10 (16.1) 0 1 (1.6) 5 (8.1) |
BCVA: best corrected visual acuity; CMT: central macular thickness; DM: diabetes mellitus; DME: diabetic macular edema; ETDRS: early treatment diabetic retinopathy study; IOP: intraocular pressure; PRP: panretinal photocoagulation; SD: standard deviation; SLT: selective laser trabeculoplasty.